Systemic Anti-Cancer Therapy Regimen Library
LEU AML - cytarabine 1.5 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [60 years and over]
Treatment Overview
Follows course 2 of induction treatment.
Frequency: Every 28 days or on count recovery.
Cycles 1 to 2 - 28 days - Courses 3 and 4
Cycle details
Cycles 1 to 2 - 28 days - Courses 3 and 4
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| cytarabine | 1500 mg/m² Twice daily | intravenous | 1, 3, 5 | 4 hours |
| prednisolone acetate 1% (10 mg/mL) eye drops * | 1 Drop Every four hours | application to the eye | 1 to 7 |
Full details
Cycles 1 to 2 - 28 days - Courses 3 and 4
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 1500 mg/m² Twice daily | intravenous | 4 hours |
Instructions:
Every 12 hours for 2 doses on day 1. |
| prednisolone acetate 1% (10 mg/mL) eye drops * | 1 Drop Every four hours | application to the eye |
Instructions:
Instil ONE drop into each eye every FOUR hours on days 1 to 7. |
Day: 2
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| prednisolone acetate 1% (10 mg/mL) eye drops * | 1 Drop Every four hours | application to the eye |
Instructions:
Instil ONE drop into each eye every FOUR hours on days 1 to 7. |
Day: 3
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 1500 mg/m² Twice daily | intravenous | 4 hours |
Instructions:
Every 12 hours for 2 doses on day 3. |
| prednisolone acetate 1% (10 mg/mL) eye drops * | 1 Drop Every four hours | application to the eye |
Instructions:
Instil ONE drop into each eye every FOUR hours on days 1 to 7. |
Day: 4
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| prednisolone acetate 1% (10 mg/mL) eye drops * | 1 Drop Every four hours | application to the eye |
Instructions:
Instil ONE drop into each eye every FOUR hours on days 1 to 7. |
Day: 5
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| cytarabine | 1500 mg/m² Twice daily | intravenous | 4 hours |
Instructions:
Every 12 hours for 2 doses on day 5. |
| prednisolone acetate 1% (10 mg/mL) eye drops * | 1 Drop Every four hours | application to the eye |
Instructions:
Instil ONE drop into each eye every FOUR hours on days 1 to 7. |
Day: 6
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| prednisolone acetate 1% (10 mg/mL) eye drops * | 1 Drop Every four hours | application to the eye |
Instructions:
Instil ONE drop into each eye every FOUR hours on days 1 to 7. |
Day: 7
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| prednisolone acetate 1% (10 mg/mL) eye drops * | 1 Drop Every four hours | application to the eye |
Instructions:
Instil ONE drop into each eye every FOUR hours on days 1 to 7. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Antifungal prophylaxis: | Routine antifungal prophylaxis recommended |
| Antiviral prophylaxis for herpes virus: | Routine antiviral prophylaxis recommended |
| Emetogenicity: | Medium |
| Growth factor support: | Variable |
| Ocular toxicity risk: | High - administer corticosteroid eyedrops to minimise corneal toxicity |
| Tumour lysis syndrome prophylaxis: | Tumour lysis syndrome prophylaxis may be considered |
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
Growth factor support: If patient in complete remission, consider pegFILGRASTIM 6 mg subcutaneous on day 6.
Tumour lysis syndrome prophylaxis: Required if patient is not in complete remission.
References
AML17 trial protocol Version 10.2 dated June 2019.
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.